ATEC reported Q4 2025 total revenue of USD 213 million and FY 2025 total revenue of USD 764 million (up 25%). Q4 2025 GAAP gross margin was 70% (non-GAAP 71%) and FY 2025 GAAP gross margin was 70% (non-GAAP 70%). Q4 2025 GAAP net loss was USD 22 million, while non-GAAP net income was USD 9 million; FY 2025 GAAP net loss was USD 143 million, while non-GAAP net income was USD 8 million. Q4 2025 adjusted EBITDA was USD 33 million (16% margin) and FY 2025 adjusted EBITDA was USD 93 million (12% margin). Ending cash balance was USD 161 million. In Q4, surgical revenue was USD 190 million (up 21%), net new surgeon users increased 23%, and ATEC generated USD 8 million of free cash flow (USD 3 million for FY 2025). The company announced the clearance and release of its Valence intraoperative platform and highlighted continued momentum in lateral and deformity procedures and the proliferation of EOS Insight. For FY 2026, ATEC reiterated total revenue expected to approximate USD 890 million (about 17% growth), including surgical revenue of about USD 805 million and EOS revenue of about USD 85 million, with adjusted EBITDA guidance of about USD 134 million and expected free cash flow of at least USD 20 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphatec Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602241605BIZWIRE_USPR_____20260224_BW093592) on February 24, 2026, and is solely responsible for the information contained therein.
Comments